Virbac Posts Strong H1 2026 Growth on Supercharge Platforms
Event summary
- H1 2026 revenue reached €768m, up +7.4% at CERS vs H1 2025 (+4.0% actual)
- Companion animal segment grew +10.0%, farm animal +6.7%; Supercharge platforms (excl. Thyronorm) rose ~+12% at CERS
- Thyronorm acquisition contributed 1.4 percentage points to overall growth
- Full-year guidance confirmed at upper end: 5.5%-7.5% revenue growth and ~17% adjusted operating margin
The big picture
Virbac's H1 2026 results reflect robust demand in both companion and farm animal segments, with Supercharge platforms driving double-digit growth. The company's strategic M&A approach, exemplified by the Thyronorm acquisition, underscores its focus on expanding endocrinology capabilities. With full-year guidance reaffirmed at the upper end, Virbac is positioning itself to capitalize on structural trends in veterinary healthcare.
What we're watching
- Geographic Expansion
- Whether Virbac can sustain double-digit growth in North America amid temporary manufacturing challenges.
- Pricing Strategy
- The impact of ~+2% price increases on volume/mix dynamics in H2 2026.
- M&A Synergies
- How Thyronorm's integration will further bolster Virbac's endocrinology presence globally.